ArticleCancer medicine2025
Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany centers screen all recipients for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). This approach may add substantial burdens of cost, incidental findings, and, depending on the imaging modality, radiation and/or contrast-induced complications. We created simple criteria to help clinicians identify low-risk patients in whom post-LT surveillance offers marginal utility.
methodsCriteria were developed retrospectively using adults with HCC who underwent LT at the University of Cincinnati from 2000 to 2014. Low-risk patients had none of the following at LT: (1) outside Milan criteria, (2) alpha-fetoprotein ≥ 200 ng/mL, (3) prior hepatectomy with vascular invasion or unknown histology, and (4) any vascular invasion or > 3 lesions on explant, or extrahepatic extension noted intraoperatively. Criteria were retrospectively validated in adults transplanted for HCC at Mass General Brigham from 2015 to 2023 and prospectively assessed at Cincinnati where low-risk patients received no post-LT surveillance.
resultsAmong 132 development cohort patients, 14 (10.6%) developed recurrent HCC at a median of 2.0 (range 0.1-9.7) years. Only 1 (1.1%) of the 91 (68.9%) patients deemed low-risk by the proposed criteria developed recurrence compared to 13 (31.7%) of the high-risk patients (p < 0.001). In the validation cohort (n = 188), recurrence occurred in 1 (0.9%) of 114 (60.6%) low-risk and 16 (21.6%) high-risk patients. In the prospective cohort (n = 55), none of 42 (76.4%) low-risk patients developed recurrence versus 3 (23.1%) high-risk patients (p = 0.011) after 8.0 (0.1-9.4) years of follow-up. The criteria performed similarly to the RETREAT score 0 across cohorts (n = 375) in identifying patients without recurrence as low-risk (negative predictive value 99.2% vs. 97.1%) but required screening significantly fewer patients (34.1% vs. 81.9%).
conclusionsThese prospectively validated criteria offer clinicians a practical tool for easily and accurately determining which patients would benefit from surveillance for HCC recurrence after LT. Surveillance targeting only high-risk patients could reduce the harms of excess screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.